Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $15.0 million.

  • Voyager Therapeutics' Accumulated Expenses rose 3068.52% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 3068.52%. This contributed to the annual value of $14.2 million for FY2024, which is 1576.41% down from last year.
  • Per Voyager Therapeutics' latest filing, its Accumulated Expenses stood at $15.0 million for Q3 2025, which was up 3068.52% from $12.0 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Accumulated Expenses registered a high of $16.8 million during Q4 2023, and its lowest value of $7.2 million during Q2 2022.
  • Over the past 5 years, Voyager Therapeutics' median Accumulated Expenses value was $11.0 million (recorded in 2021), while the average stood at $10.7 million.
  • Per our database at Business Quant, Voyager Therapeutics' Accumulated Expenses plummeted by 4773.14% in 2021 and then skyrocketed by 11523.8% in 2023.
  • Over the past 5 years, Voyager Therapeutics' Accumulated Expenses (Quarter) stood at $11.0 million in 2021, then dropped by 28.62% to $7.8 million in 2022, then surged by 115.24% to $16.8 million in 2023, then dropped by 15.76% to $14.2 million in 2024, then rose by 5.52% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q3 2025, $12.0 million for Q2 2025, and $9.1 million during Q1 2025.